Loading...

TIL INSTIL BIO INC Expansion Plans 8-K Filing

NSTL

TL

INSTIL BIO INC

(TIL)

2025 8-K

Financial Results Update

Accountant Change

Corporate Update

Agreement Termination

Quarterly Update

Financial Update

Product Expansion

Clinical Development

Investor Meetings

Financial Statements

Stock Sale Agreement

Financial Results

Clinical Progress

Financial Results

Corporate Update

Workforce Reduction

Investor Presentation

Financial Results

License and Collaboration A...

Lease Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Retention Bonus Agreement

Restructuring Plan Approval

Reverse Stock Split

Reverse Stock Split

Financial Update

Results of Operations and F...

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Retention Bonus Agreements

Costs Associated with Exit ...

Clinical Trial Resumption

External Links:

On May 22, 2025, Instil Bio, Inc. and ImmuneOnco reported that their Phase 2 trial for the combinatory treatment '2510 in NSCLC is on track, expecting to enroll 60 patients by Q3 2025 and share results in H2 2025, reporting a 23.1% objective response rate in earlier trials.

AI Assistant

INSTIL BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.